FDA orders class-wide GLP-1 label update for potential risk of rare eye disease
- FDA is requiring all approved GLP-1 receptor agonists to add a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to Warnings and Precautions; indications are unchanged.
- Twelve products are affected, including Wegovy, Ozempic, Zepbound and Mounjaro.
- A trial meta-analysis found 6.4 NAION events per 100,000 patient-years with GLP-1s versus 3.8 for comparators; FDA found no mechanism in animal data.
💡 Points Based on public reports
A Warnings-section addition rather than a boxed warning keeps the commercial hit modest, and the absolute difference is small. Still, class-wide wording denies Novo and Lilly any differentiation on eye safety. What's missing is mechanism and per-drug data; watch for ophthalmology-driven prescribing caution in high-risk patients.
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease ↗